Ursodeoxycholic acid - Retrophin

Drug Profile

Ursodeoxycholic acid - Retrophin

Alternative Names: L-UDCA; liquid formulation ursodeoxycholic acid; ursodeoxycholic acid liquid

Latest Information Update: 29 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asklepion Pharmaceuticals
  • Developer Retrophin
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants
  • Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Primary biliary cirrhosis

Most Recent Events

  • 20 Jun 2016 Retrophin acquires ursodeoxycholic acid (liquid formulation) from Asklepion Pharmaceuticals
  • 20 Jun 2016 Retrophin announces intention to submit NDA to US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top